Last edition
News about "Astex Pharmaceuticals"
Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer
Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.
Astex Pharmaceuticals | 07/07/2026 | By News Bureau
Astex Partners with Genentech on Breast Cancer Therapy Research
Astex has entered an exclusive research and licensing agreement with Genentech for a breast cancer therapy program, with potential deal value exceeding USD 490 million plus tiered royalties.
Astex Pharmaceuticals | 07/07/2026 | By News Bureau
US FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant NSCLC
Calderasib has received US FDA Breakthrough Therapy Designation for certain patients with newly diagnosed metastatic KRAS G12C-mutant Non-Small Cell Lung Cancer (NSCLC), supported by promising phase 1 KANDLELIT-001 trial data highlighting its potential as a next-generation, highly potent and selective KRAS G12C inhibitor.
Astex Pharmaceuticals | 30/05/2026 | By News Bureau | 112
Astex Expands Drug Discovery Collaboration With Merck
Astex Expands Drug Discovery Collaboration With Merck
Astex Pharmaceuticals | 09/08/2023 | By Sudeep Soparkar | 972
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy